上海市人民政府办公厅今日印发《上海市全面深化药品医疗器械监管改革促进医药产业高质量发展的若 干措施》的通知，其中提到，强化标准引领。积极参与药品医疗器械国家标准制修订和国际标准协调。 发挥新型标准化技术组织作用，推进人工智能医疗器械、医用机器人、脑机接口、粒子治疗设备、创新 中医诊疗设备、细胞与基因治疗等前沿技术的标准化研究。持续开展中药饮片、中药配方颗粒及中医医 疗器械标准研究，依托国际标准化组织/中医药技术委员会（ISO/TC249）等国际标准化平台，制定中医 药国际标准。支持药品医疗器械生产过程数字化追溯等团体标准制订。 ...

公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 消息面上，健倍苗苗公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同比增加约 7.7%；公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%；每股盈利14.12港仙，中期股息每 股普通股9.75港仙。 健倍苗苗(02161)涨超5%，截至发稿，涨5.19%，报3.04港元，成交额155.88万港元。 ...

公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 消息面上，健倍苗苗公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同比增加约 7.7%；公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%；每股盈利14.12港仙，中期股息每 股普通股9.75港仙。 智通财经APP获悉，健倍苗苗(02161)涨超5%，截至发稿，涨5.19%，报3.04港元，成交额155.88万港 元。 ...

11月17日，佐力药业跌2.16%，成交额1.64亿元。两融数据显示，当日佐力药业获融资买入额2013.53万 元，融资偿还2075.26万元，融资净买入-61.72万元。截至11月17日，佐力药业融资融券余额合计5.70亿 元。 融资方面，佐力药业当日融资买入2013.53万元。当前融资余额5.68亿元，占流通市值的4.71%，融资余 额超过近一年60%分位水平，处于较高位。 融券方面，佐力药业11月17日融券偿还0.00股，融券卖出3200.00股，按当日收盘价计算，卖出金额5.51 万元；融券余量9.74万股，融券余额167.63万元，超过近一年90%分位水平，处于高位。 资料显示，浙江佐力药业股份有限公司位于浙江省德清县阜溪街道志远北路388号，成立日期2000年1月 28日，上市日期2011年2月22日，公司主营业务涉及药用真菌乌灵系列和百令片产品、中药饮片及中药 配方颗粒的研发、生产与销售。主营业务收入构成为：乌灵系列56.07%，中药饮片系列21.85%，其他 产品10.11%，百令系列7.08%，中药配方颗粒4.62%，其他(补充)0.26%。 截至9月30日，佐力药业股东户数4.14万，较上 ...

Core Viewpoint - The Anhui Provincial Drug Administration has introduced measures to enhance the regulation of pharmaceuticals and medical devices, aiming to promote high-quality development in the pharmaceutical industry [1][2]. Group 1: Reform Measures - The newly issued measures include 21 specific reform initiatives across five key areas, focusing on supporting drug and medical device research and innovation, as well as the development of traditional Chinese medicine [1]. - Anhui will strengthen tracking services for drug and medical device research, implementing a tailored approach for each company with comprehensive guidance throughout the process [1]. Group 2: Enhancing Approval Processes - The measures aim to improve the efficiency of drug and medical device review and approval processes by enhancing the capabilities of the review team and optimizing the approval workflow [2]. - A tracking service mechanism will be established for key parks, projects, and innovative products to facilitate faster market entry for urgently needed drugs and devices [2]. Group 3: Promoting Industry Compliance - The measures encourage the development of pharmaceutical industry clusters and support the establishment of high-standard specialty industrial parks in regions with existing advantages [2]. - There will be an emphasis on enhancing the regulatory quality of new pharmaceutical distribution models and fostering collaboration in innovative research and development [2].

智通财经APP讯，健倍苗苗(02161)公布截至2025年9月30日止6个月中期业绩，收益约为4.3亿港元，同 比增加约7.7%。公司权益持有人应占溢利约为1.15亿港元，同比增加约20.0%。每股盈利14.12港仙，中 期股息每股普通股9.75港仙。 公告称，业绩增长主要来自核心品牌的强劲销售表现，尤其是品牌药分部的何济公及品牌中药分部的保 济丸，得益于专注的品牌管理及有效的市场推广执行。集团的中药配方颗粒业务亦表现稳定，为品牌健 康业务组合作出持续贡献。 ...

Core Viewpoint - Zhaoli Pharmaceutical's stock has experienced a decline of 2.05% on November 17, with a current price of 17.23 CNY per share and a market capitalization of 12.085 billion CNY, despite a year-to-date increase of 16.67% [1] Financial Performance - For the period from January to September 2025, Zhaoli Pharmaceutical reported a revenue of 2.28 billion CNY, reflecting a year-on-year growth of 11.48%, and a net profit attributable to shareholders of 510 million CNY, which is a 21.00% increase compared to the previous year [2] - Cumulative cash dividends since the company's A-share listing amount to 1.442 billion CNY, with 942 million CNY distributed over the last three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,400, up by 7.31%, while the average number of circulating shares per person decreased by 6.82% to 14,562 shares [2] - Among the top ten circulating shareholders, the "Innovative Medicine" fund holds 6.8549 million shares, an increase of 280,700 shares, while the "Southern CSI 1000 ETF" holds 6.4172 million shares, a decrease of 58,800 shares [3] Stock Performance - Zhaoli Pharmaceutical's stock has seen a decline of 2.43% over the last five trading days, 6.92% over the last twenty days, and 13.29% over the last sixty days [1] - The stock's trading volume on November 17 was 58.7402 million CNY, with a turnover rate of 0.56% [1] Business Overview - Zhaoli Pharmaceutical, established on January 28, 2000, and listed on February 22, 2011, specializes in the research, production, and sales of medicinal fungi, traditional Chinese medicine pieces, and formula granules [1] - The company's main revenue sources include the Wuling series (56.07%), traditional Chinese medicine pieces (21.85%), and other products [1] Industry Classification - Zhaoli Pharmaceutical is classified under the pharmaceutical and biotechnology sector, specifically in traditional Chinese medicine [1] - The company is associated with various concept sectors, including value growth, cell therapy, precision medicine, cancer treatment, and innovative drugs [1]

证券之星消息，11月13日南向资金减持326.6万股中国中药（00570.HK）。近5个交易日中，获南向资金 减持的有4天，累计净减持402.8万股。近20个交易日中，获南向资金减持的有11天，累计净减持111.0万 股。截至目前，南向资金持有中国中药（00570.HK）15.83亿股，占公司已发行普通股的31.42%。 | 交易日 | 持股总数(股) | 持股变动(股) | 变动幅度 | | --- | --- | --- | --- | | 2025-11-13 | 15.83 Z | -326.60万 | -0.21% | | 2025-11-12 | 15.86亿 | -225.60万 | -0.14% | | 2025-11-11 | 15.88 乙 | 246.80万 | 0.16% | | 2025-11-10 | 15.86 乙 | -18.20万 | -0.01% | | 2025-11-07 | 15.86亿 | -79.20万 | -0.05% | 中国中药控股有限公司是一家主要从事中药制造及销售的投资控股公司。该公司通过四个分部运营业 务。一方分部主要从事中药配方颗粒、中药大健康产品及 ...

Group 1: Product Strategy - The company focuses on key products such as the patented "Panlong Seven Tablets," which is part of a diverse portfolio covering 12 functional categories and over 100 product specifications [2] - The product range includes 19 dosage forms and 74 approved drug production numbers, along with health food and health products [2] - Future product development will emphasize functional health foods aimed at increasing bone density and other health benefits [3] Group 2: Marketing Network - The company has established a comprehensive marketing network covering over 5,000 tier-one medical institutions and more than 30,000 retail pharmacies [3] - Collaboration with over 650 commercial partners across 30 provincial administrative regions supports multi-category product sales [3] - The company is leveraging "Internet + Medicine" trends to enhance digital marketing and brand influence [3] Group 3: Traditional Chinese Medicine (TCM) Business - The company has completed the filing of 411 varieties of TCM granules, all approved by the National Medical Products Administration [3] - The company is actively advancing the listing of these products in 18 provinces, including major markets like Beijing and Shandong [3] - A combined model of self-operated teams and agents is being used to develop sales channels, focusing on key regions [3]

Investment Rating - The investment rating for the company is "Buy" and is maintained [6]. Core Views - The company reported a revenue of 2.28 billion yuan for the first nine months of 2025, representing a year-on-year growth of 11.48%. The net profit attributable to the parent company was 510 million yuan, up 21.00% year-on-year [3][4]. - In Q3 2025, the company achieved a revenue of 680 million yuan, a year-on-year increase of 10.32%, with a net profit of 136 million yuan, growing 8.81% year-on-year [3][4]. - The core products, including the Wuling series and the Bailin series, have shown significant growth, with revenues increasing by 6.98%, 29.58%, and 57.41% respectively for the Wuling series, Bailin series, and traditional Chinese medicine formula granules [10]. Financial Performance - The gross profit margin for Q3 2025 was 59.72%, an increase of 0.47 percentage points year-on-year, while the net profit margin was 20.06%, a decrease of 0.28 percentage points year-on-year [10]. - The company’s R&D expenses increased by 42.55% year-on-year to 17 million yuan, with an R&D expense ratio of 2.44% [10]. - The company expects net profits for 2025, 2026, and 2027 to be 638 million yuan, 800 million yuan, and 1.018 billion yuan respectively, with corresponding EPS of 0.91 yuan, 1.14 yuan, and 1.45 yuan [10].